Bristol-Myers' Opdivo fails late-stage study in lung cancer patients

Aug 5 (Reuters) - Bristol-Myers Squibb Co said its
blockbuster immunotherapy, Opdivo, failed to improve survival in
previously untreated patients with a form of lung cancer,
without their disease...